Advances in plasma skin regeneration.
Plasma skin regeneration (PSR) is a novel method of resurfacing that uses plasma energy to create a thermal effect on the skin. PSR is different from lasers, light sources, and ablative lasers in that it is not chromophore dependent and does not vaporize tissue, but leaves a layer of intact, desiccated epidermis that acts as a natural biologic dressing and promotes wound healing and rapid recovery. Histological studies performed on plasma resurfacing patients have confirmed continued collagen production, reduction of elastosis, and progressive skin rejuvenation beyond 1 year after treatment. PSR has received US Food and Drug Administration 510 (k) clearance for treatment of rhytides of the body, superficial skin lesions, actinic keratoses, viral papillomata, and seborrheic keratoses. PSR also has beneficial effects in the treatment of other conditions including dyschromias, photoaging, skin laxity, and acne scars. The safety profile of PSR is excellent, and there have been no reports of demarcation lines in perioral, periorbital, or jawline areas, as can sometimes be observed following CO2 resurfacing. PSR is effective in improving facial and periorbital rhytides and can be used on nonfacial sites, including the hands, neck, and chest. Numerous treatment protocols with variable energy settings allow for individualized treatments and provide the operator with fine control over the degree of injury and length of subsequent recovery time.
Foster
K Wade
KW
Moy-Fincher Medical Group, UCLA Medical Plaza, Los Angeles, CA 90024, USA.
Moy
Ronald L
RL
Fincher
Edgar F
EF
D003357:Cosmetic Techniques / Q000009:adverse effects / Q000295:instrumentation*; D045462:Endothelium-Dependent Relaxing Factors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D028022:Low-Level Light Therapy / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D009569:Nitric Oxide / Q000627:therapeutic use; D012038:Regeneration; D012060:Rejuvenation; D015595:Skin Aging; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014945:Wound Healing
D045462:Endothelium-Dependent Relaxing Factors; D009569:Nitric Oxide